Thursday, August 11, 2011
DSR Demolition’s sweet charity
Source : http://www.prlog.org/11590493-dsr-demolitions-sweet-charity.html permits to republish here.at http://asbestos-mesothelioma-blognewsinfo.blogspot.com/
Wednesday, August 10, 2011
Tuesday, August 9, 2011
Monday, August 8, 2011
Friday, August 5, 2011
Thursday, August 4, 2011
EMLab P&K's Denver Asbestos Lab Receives NVLAP Accreditation for Asbestos Analysis
The Denver, CO lab is EMLab P&K's tenth NVLAP-accredited asbestos lab for asbestos analysis (NVLAP Lab Code 500053-0). 
EMLab P&K announces the accreditation of its asbestos lab in Denver, Colorado by the National Volunteer Laboratory Accreditation Program (NVLAP) for PLM bulk asbestos analysis (NVLAP Lab Code 500053-0). EMLab P&K now has ten (10) NVLAP-accredited laboratories for asbestos analysis. The Denver lab is also registered with the state of Colorado as an asbestos laboratory through Colorado’s Department of Public Health and Environment (Colorado DPH&E # 18529).
EMLab P&K’s Denver lab is located at: 1746 Cole Blvd., Building 21, Suite 225, Lakewood, CO 80401. EMLab P&K’s clients can now send your asbestos PLM samples (EPA Method 600/R-93/116) to our Denver lab for analysis. The lab is also accredited by AIHA (EMLAP # 176649) for mold analysis.
"With our Denver laboratory receiving NVLAP accreditation, EMLab P&K continues to demonstrate it is among the very best asbestos laboratories in the nation. This recognition shows that the analytical data that we produce is always of the highest quality. Because major health and financial decisions are made based on our laboratory’s results and on our quality system, it is very important that the data we produce and our QA system ensures the highest quality. EMLab P&K’s NVLAP accreditation is a mark of this capability as an asbestos laboratory," states Tim Costello, EMLab P&K’s Director of Quality Assurance.
NVLAP provides unbiased third-party recognition of quality performance by a laboratory through strict series of assessments. NVLAP accreditation represents a laboratory’s proven ability to meet or exceed technical requirements set by NVLAP management. NVLAP is in full conformance with the standards of the International Organization for Standardization (ISO) and the International Electrotechnical Commission (IEC) and has become an industry standard for excellence. Areas of assessment include: quality systems, personnel, equipment, measurement traceability, sampling, accommodation and environment, test and calibration methods, handling and reports.
About EMLab P&K
EMLab P&K, a TestAmerica company, is one of the leading commercial indoor air quality laboratories in North America with over 60 service and drop-off locations throughout the United States. EMLab P&K specializes in analyzing air and surface samples to identify mold, bacteria, fungi, asbestos, and allergens. EMLab P&K also offers USP 797 testing, PCR testing, radon analysis, and materials testing. EMLab P&K has an extensive list of accreditations from leading organizations and government agencies including: AIHA, NVLAP, CA-ELAP, NY-ELAP, Texas DSHS, and other accrediting programs.
LinkedIn: Follow EMLab P&K on LinkedIn
Source : http://www.widepr.com/press_release/17738/emlab_p_k_s_denver_asbestos_lab_receives_nvlap_accreditation_for_asbestos_analysis.html permits to republish here.at http://asbestos-mesothelioma-blognewsinfo.blogspot.com/
EMLab P&K’s Denver lab is located at: 1746 Cole Blvd., Building 21, Suite 225, Lakewood, CO 80401. EMLab P&K’s clients can now send your asbestos PLM samples (EPA Method 600/R-93/116) to our Denver lab for analysis. The lab is also accredited by AIHA (EMLAP # 176649) for mold analysis.
"With our Denver laboratory receiving NVLAP accreditation, EMLab P&K continues to demonstrate it is among the very best asbestos laboratories in the nation. This recognition shows that the analytical data that we produce is always of the highest quality. Because major health and financial decisions are made based on our laboratory’s results and on our quality system, it is very important that the data we produce and our QA system ensures the highest quality. EMLab P&K’s NVLAP accreditation is a mark of this capability as an asbestos laboratory," states Tim Costello, EMLab P&K’s Director of Quality Assurance.
NVLAP provides unbiased third-party recognition of quality performance by a laboratory through strict series of assessments. NVLAP accreditation represents a laboratory’s proven ability to meet or exceed technical requirements set by NVLAP management. NVLAP is in full conformance with the standards of the International Organization for Standardization (ISO) and the International Electrotechnical Commission (IEC) and has become an industry standard for excellence. Areas of assessment include: quality systems, personnel, equipment, measurement traceability, sampling, accommodation and environment, test and calibration methods, handling and reports.
About EMLab P&K
EMLab P&K, a TestAmerica company, is one of the leading commercial indoor air quality laboratories in North America with over 60 service and drop-off locations throughout the United States. EMLab P&K specializes in analyzing air and surface samples to identify mold, bacteria, fungi, asbestos, and allergens. EMLab P&K also offers USP 797 testing, PCR testing, radon analysis, and materials testing. EMLab P&K has an extensive list of accreditations from leading organizations and government agencies including: AIHA, NVLAP, CA-ELAP, NY-ELAP, Texas DSHS, and other accrediting programs.
EMLab P&K
Cole Mackelprang
1150 Bayhill Drive, Suite 100
San Bruno, California
United States, 94066
Voice 866-888-6653
Fax 650-829-5852
Email: information@emlabpk.com
Website: EMLab P&KLinkedIn: Follow EMLab P&K on LinkedIn
Source : http://www.widepr.com/press_release/17738/emlab_p_k_s_denver_asbestos_lab_receives_nvlap_accreditation_for_asbestos_analysis.html permits to republish here.at http://asbestos-mesothelioma-blognewsinfo.blogspot.com/
Wednesday, August 3, 2011
New Avenues Open Up for Mesothelioma Targeted Therapy
Newswise — July 25, 2011 (Philadelphia, PA) --Researchers from the lab of Antonio Giordano, M.D., Ph.D., the Founder and Director of the Sbarro Institute for Cancer Research and Molecular Medicine, have identified new potential anti-tumor agents that might be effective in treating mesothelioma, one of the deadliest cancer tumors.
Scientists tested new pyrazolo [3,4-d ]pyrimidine derivative inhibitors of the SRC kinase, a well-established molecular target in cancer therapy. They found that these SRC inhibitors effectively induced cell death, through apoptosis, in mesothelioma cell lines without affecting the normal mesothelial cells, thus supporting a possible use of these agents as a safe treatment for mesothelioma.
Their findings appear in the journal Oncogene.
Interestingly, the researchers also found that the SRC inhibitors induced cell death was accompanied by an increase in the nuclear stability of the cyclin-dependent kinase inhibitor p27. This is “particularly intriguing considering that the loss of nuclear p27 expression is a well established adverse prognostic factor in mesothelioma and p27 nuclear localization is crucial for its tumor suppressive function.” said the leading author of the study, Paola Indovina, Ph.D. of the University of Siena and assistant Professor at the Sbarro Institute.
“We think that these data represent a timely contribution and suggest that p27 status should be carefully analyzed when evaluating the use of kinase inhibitors affecting SRC in clinical trials for patients with mesothelioma,” said the corresponding author of the study Francesca Pentimalli, Ph.D. of the National Cancer Institute- “Pascale Foundation” - CROM- Cancer Research Center of Mercogliano in Avellino, Italy and assistant Professor at the Sbarro Institute.
“The findings support SRC as a critical therapeutic target in mesothelioma and reveal a new mechanism, dependent on p27 nuclear stabilization, by which SRC inhibition can induce apoptosis in mesothelioma cell lines, providing a new rationale for the use of SRC inhibitors in mesothelioma therapy,” says Prof. Antonio Giordano, another lead author. “It also shows that in this context, p27 is required to induce apoptosis in mesothelioma cell lines and, although this mechanism still needs to be precisely dissected, it adds further evidence supporting an active role for p27 in mediating apoptosis.”
The study was done in collaboration with Maurizio Botta full Professor of Medicinal Chemistry and Dean of the Faculty of Pharmacy, University of Siena, also adjunct Professor at the Sbarro Institute, who developed these new SRC inhibitors along with Prof. Silvia Schenone of the University of Genoa, Genoa, Italy.
###
The Sbarro Health Research Organization Center for Biotechnology Research funds the Sbarro Institute for Cancer Research and Molecular Medicine, a leading nonprofit research center for cancer, diabetes, and cardiovascular disease. The Director of the Center is Antonio Giordano, M.D., Ph.D., an internationally known pathologist and geneticist.
The Human Health Foundation is a nonprofit organization dedicated to biomedical research and health education based in Spoleto-Terni, Italy.
Source : http://www.newswise.com/articles/possible-new-approach-to-treating-mesothelioma permits to republish here.at http://asbestos-mesothelioma-blognewsinfo.blogspot.com/
Scientists tested new pyrazolo [3,4-d ]pyrimidine derivative inhibitors of the SRC kinase, a well-established molecular target in cancer therapy. They found that these SRC inhibitors effectively induced cell death, through apoptosis, in mesothelioma cell lines without affecting the normal mesothelial cells, thus supporting a possible use of these agents as a safe treatment for mesothelioma.
Their findings appear in the journal Oncogene.
Interestingly, the researchers also found that the SRC inhibitors induced cell death was accompanied by an increase in the nuclear stability of the cyclin-dependent kinase inhibitor p27. This is “particularly intriguing considering that the loss of nuclear p27 expression is a well established adverse prognostic factor in mesothelioma and p27 nuclear localization is crucial for its tumor suppressive function.” said the leading author of the study, Paola Indovina, Ph.D. of the University of Siena and assistant Professor at the Sbarro Institute.
“We think that these data represent a timely contribution and suggest that p27 status should be carefully analyzed when evaluating the use of kinase inhibitors affecting SRC in clinical trials for patients with mesothelioma,” said the corresponding author of the study Francesca Pentimalli, Ph.D. of the National Cancer Institute- “Pascale Foundation” - CROM- Cancer Research Center of Mercogliano in Avellino, Italy and assistant Professor at the Sbarro Institute.
“The findings support SRC as a critical therapeutic target in mesothelioma and reveal a new mechanism, dependent on p27 nuclear stabilization, by which SRC inhibition can induce apoptosis in mesothelioma cell lines, providing a new rationale for the use of SRC inhibitors in mesothelioma therapy,” says Prof. Antonio Giordano, another lead author. “It also shows that in this context, p27 is required to induce apoptosis in mesothelioma cell lines and, although this mechanism still needs to be precisely dissected, it adds further evidence supporting an active role for p27 in mediating apoptosis.”
The study was done in collaboration with Maurizio Botta full Professor of Medicinal Chemistry and Dean of the Faculty of Pharmacy, University of Siena, also adjunct Professor at the Sbarro Institute, who developed these new SRC inhibitors along with Prof. Silvia Schenone of the University of Genoa, Genoa, Italy.
###
The Sbarro Health Research Organization Center for Biotechnology Research funds the Sbarro Institute for Cancer Research and Molecular Medicine, a leading nonprofit research center for cancer, diabetes, and cardiovascular disease. The Director of the Center is Antonio Giordano, M.D., Ph.D., an internationally known pathologist and geneticist.
The Human Health Foundation is a nonprofit organization dedicated to biomedical research and health education based in Spoleto-Terni, Italy.
Source : http://www.newswise.com/articles/possible-new-approach-to-treating-mesothelioma permits to republish here.at http://asbestos-mesothelioma-blognewsinfo.blogspot.com/
Subscribe to:
Posts (Atom)